Correction: Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation
Journal: Annals of Internal Medicine (2022)

CorrectionsJanuary 2023Correction: Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial FibrillationFREEThis correction concerns the following article:Original ResearchNov 2022Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial FibrillationWallis C.Y. Lau, PhD*, Carmen Olga Torre, MSc*, Kenneth K.C. Man, PhD, Henry Morgan Stewart, PhD, Sarah Seager, BAWallis C.Y. Lau, PhD*Research Department of Practice and Policy, University College London School of Pharmacy, London, United Kingdom, Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom, Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, and Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong (W.C.Y.L., K.K.C.M.), Carmen Olga Torre, MSc*IQVIA, Real-World Solutions, Brighton, United Kingdom (C.O.T., H.M.S., S.S.), Kenneth K.C. Man, PhDResearch Department of Practice and Policy, University College London School of Pharmacy, London, United Kingdom, Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom, Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, and Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong (W.C.Y.L., K.K.C.M.), Henry Morgan Stewart, PhDIQVIA, Real-World Solutions, Brighton, United Kingdom (C.O.T., H.M.S., S.S.), Sarah Seager, BAIQVIA, Real-World Solutions, Brighton, United Kingdom (C.O.T., H.M.S., S.S.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L22-0482 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the article by Lau and colleagues (1), the authors identified an error in describing the dosage of edoxaban in the Statistical Analysis section. The edoxaban dosing regimen was written as "60 mg twice daily" and "30 mg twice daily"; this should be "once daily" in both places and has been corrected online.Reference1. Lau WCY, Torre CO, Man KKC, et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation. A multinational population-based cohort study. Ann Intern Med. 2022;175:1515-24. [PMID: 36315950] doi:10.7326/M22-0511 LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationThis article was published at Annals.org on 6 December 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation Wallis C.Y. Lau , Carmen Olga Torre , Kenneth K.C. Man , Henry Morgan Stewart , Sarah Seager , Mui Van Zandt , Christian Reich , Jing Li , Jack Brewster , Gregory Y.H. Lip , Aroon D. Hingorani , Li Wei , and Ian C.K. Wong Metrics January 2023Volume 176, Issue 1Page: 144KeywordsAnticoagulantsApixabanChronic kidney diseaseClinical trialsCohort studiesDatabasesDrugsHemorrhageObservational studiesStroke ePublished: 6 December 2022 Issue Published: January 2023 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...